Search results
Showing 1251 to 1300 of 3761 results for treatment
development of patient registries for multiple sclerosis to capture long-term treatment-related outcomes. Any explanatory notes(if...
Evidence-based recommendations on metreleptin (Myalepta) for treating lipodystrophy in children and adults.
Acoramidis for treating transthyretin amyloidosis with cardiomyopathy (TA1121)
Evidence-based recommendations on acoramidis (Beyonttra) for treating wild-type or hereditary transthyretin amyloidosis with cardiomyopathy in adults.
Thousands could benefit from new take-at-home treatment for advanced prostate cancer
NICE recommends life-extending daily pill which offers hope for people who cannot take standard treatment.
Recommendation ID NG80/6 Question Starting asthma treatment:- In adults, young people and children with asthma who have not been treated
Recommendation ID NG25/7 Question At what gestation should treatment with prophylactic vaginal progesterone for the prevention of...
Rifaximin for preventing episodes of overt hepatic encephalopathy (TA337)
Evidence-based recommendations on rifaximin (Targaxan) for preventing episodes of hepatic encephalopathy in adults.
diagnosis and management Fertility problems: assessment and treatment Fetal monitoring in labour - Heavy menstrual
Evidence-based recommendations on implantable cardioverter defibrillators and cardiac resynchronisation therapy for people with ventricular arrhythmias or heart failure
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer (TA411)
Evidence-based recommendations on necitumumab (Portrazza) for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer in adults who have not had chemotherapy.
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
In development Reference number: GID-TA11519 Expected publication date: 12 June 2026
Tofacitinib for treating juvenile idiopathic arthritis (TA735)
Evidence-based recommendations on tofacitinib for treating juvenile idiopathic arthritis.
Sapropterin for treating hyperphenylalaninaemia in phenylketonuria (TA729)
Evidence-based recommendations on sapropterin for treating hyperphenylalaninaemia in phenylketonuria.
Finerenone for treating chronic kidney disease in type 2 diabetes (TA877)
Evidence-based recommendations on finerenone (Kerendia) for stage 3 and 4 chronic kidney disease (with albuminuria) associated with type 2 diabetes in adults.
This guideline covers the short-term management of violence and aggression in adults (aged 18 and over), young people (aged 13 to 17) and children (aged 12 and under). It is relevant for mental health, health and community settings. The guideline aims to safeguard both staff and people who use services by helping to prevent violent situations and providing guidance to manage them safely when they occur.
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA1119)
Evidence-based recommendations on venetoclax (Venclyxto) with obinutuzumab (Gazyvaro) for untreated chronic lymphocytic leukaemia in adults.
Show all sections
Question Early and late-onset meningitis: What is the optimal antibiotic treatment regimen for early-onset neonatal meningitis? Any...
Short-term bridging treatment with glucocorticoids:- What is the clinical and cost effectiveness of short-term bridging...
biomarkers accurately classify recurrence, progression and response to treatment? Any explanatory notes(if applicable) For a short...
Evidence-based recommendations on ertugliflozin (Steglatro) with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes in adults.
and prescriptive factors are important in determining the choice of PTSD treatment? Any explanatory notes(if applicable) To find out why...
migraine:- Is amitriptyline a clinically and cost effective prophylactic treatment for recurrent migraine? Any explanatory notes(if...
Recommendation ID NG198/1 Question Oral isotretinoin treatment: What is the efficacy of reduced dose oral isotretinoin in the management
Evidence-based recommendations on pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea in adults.
Evidence-based recommendations on semaglutide (Wegovy) for managing overweight and obesity in adults.
Patisiran for treating hereditary transthyretin amyloidosis (HST10)
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy.
Awaiting development Reference number: GID-TA11837 Expected publication date: TBC
future treatment strategies, as would more data on the relative effectiveness of ipilimumab when given as a first-line or second-line...
Electroacupuncture: Is electroacupuncture a clinically and cost-effective treatment for any subgroup of people with osteoarthritis? Any...
Birch bark extract for treating epidermolysis bullosa (HST28)
Evidence-based recommendations on birch bark extract (Filsuvez) for treating partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa in people aged 6 months and over.
predictors of biphasic reactions in people who have received emergency treatment for anaphylaxis? Any explanatory notes(if applicable)...
Setmelanotide for treating obesity caused by LEPR or POMC deficiency (HST21)
Evidence-based recommendations on setmelanotide (Imcivree) for treating obesity caused by LEPR or POMC deficiency in people 6 years and over.
In moderate OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?...
Cerebral palsy in under 25s: assessment and management (NG62)
This guideline covers diagnosing, assessing and managing cerebral palsy in children and young people from birth up to their 25th birthday. It aims to make sure they get the care and treatment they need for the developmental and clinical comorbidities associated with cerebral palsy, so that they can be as active and independent as possible.
Child maltreatment: when to suspect maltreatment in under 18s (CG89)
This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help healthcare professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.
Evidence-based recommendations on autologous chondrocyte implantation using chondrosphere (Spherox) for treating symptomatic articular cartilage defects of the knee in adults.
Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia (TA29)
Evidence-based recommendations on fludarabine (Fludara) for B-cell chronic lymphocytic leukaemia.
Managed access allows people to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Harmful sexual behaviour among children and young people (NG55)
This guideline covers children and young people who display harmful sexual behaviour, including those on remand or serving community or custodial sentences. It aims to ensure these problems don’t escalate and possibly lead to them being charged with a sexual offence. It also aims to ensure no-one is unnecessarily referred to specialist services.
Evidence-based recommendations on marstacimab (Hympavzi) for treating severe haemophilia A or B in people 12 years and over without anti-factor antibodies.
planned or in progress Advanced breast cancer: diagnosis and treatment (CG81) Updates in progress Chemotherapy for advanced breast cancer
headache:- Is topiramate a clinically and cost effective prophylactic treatment for recurrent cluster headache? Any explanatory notes(if...
In development Reference number: GID-TA11385 Expected publication date: 25 February 2026
This quality standard covers diagnosing and managing spondyloarthritis in adults aged 16 and over. It describes high-quality care in priority areas for improvement.
Eplontersen for treating hereditary transthyretin-related amyloidosis (TA1020)
Evidence-based recommendations on eplontersen (Wainzua) for treating hereditary transthyretin-related amyloidosis in adults.
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
Coeliac disease: recognition, assessment and management (NG20)
This guideline covers the recognition, assessment and management of coeliac disease in children, young people and adults.